|Articles|November 18, 2003
Anecortave acetate found to safe, effective for inhibiting CNV growthin AMD patients
Anecortave acetate (Retaane), a potent angiostatic agent, has been shownto be safe and superior to placebo in reducing loss of vision from baseline,avoiding severe vision loss, and inhibiting the growth of CNV membranesin patients with age-related macular degeneration (AMD), reported JasonS. Slakter, MD, who spoke during the American Academy of Ophthalmology annualmeeting.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ocumetics reports first-in-human data investigational accommodating IOL in severe vision loss
2
Sandoz Canada launches aflibercept biosimilar, Enzeevum
3
EnVision Summit 2026: Ultimate gathering place for ophthalmic education
4
AMD and low vision awareness month: Using the MTII to evaluate progression of GA
5
























